Search Within

Gregory J Riely

  1. "Early Drug Development Service"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (7)
Groups
  1. Department of Medicine (16)
  2. Early Drug Development Service (16)
  3. Solid Tumor Oncology Division (16)
  4. Thoracic Oncology (16)
  5. Department of Pathology and Laboratory Medicine (12)
  6. GSK Faculty (12)

More Groups

People
  1. David Hyman (15)
  2. Marc Ladanyi (9)
  3. Bob Li (8)
  4. Jose Baselga (8)
  5. Alexander Drilon (7)
  6. Charles Rudin (7)

More People

Years
  1. 2024 (1)
  2. 2020 (3)
  3. 2019 (3)
  4. 2018 (1)
  5. 2017 (5)
  6. 2016 (1)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Cancer Discovery (2)
  3. Clinical Cancer Research (2)
  4. JCO Precision Oncology (2)
  5. Journal of Thoracic Oncology (2)
  6. Nature Medicine (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (5)
  3. Elsevier Inc. (2)
  4. Nature Publishing Group (2)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor-agnostic genomic and clinical analysis of BRAF fusions identifies actionable targets
    Journal Article

    Chen, M. F.; Yang, S. R.; Tao, J. J.; Desilets, A.; Diamond, E. L.; Wilhelm, C.; Rosen, E.; Gong, Y.; Mullaney, K.; Torrisi, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers
    Meeting Abstract

    Murciano-Goroff, Y. R.; Arbour, K. C.; Offin, M. D.; Tu, H. Y. Y.; Lebow, E. S.; Shaffer, T. S.; Bertucci, C.; Hosseini, S. A.; Garg, K.; Lim, L. P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer
    Meeting Abstract

    Murciano-Goroff, Y. R.; Lebow, E. S.; Tu, H. Y.; Li, M.; Lim, L. P.; Arbour, K. C.; Travis, W.; Solit, D. B.; Ladanyi, M.; Jones, D. R.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Pan-cancer efficacy of vemurafenib in BRAF(V600)-mutant non-melanoma cancers
    Journal Article

    Subbiah, V.; Puzanov, I.; Blay, J. Y.; Chau, I.; Lockhart, A. C.; Raje, N. S.; Wolf, J.; Baselga, J.; Meric-Bernstam, F.; Roszik, J.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Efficacy of vemurafenib in patients with non–small-cell lung cancer with BRAF V600 mutation: An open-label, single-arm cohort of the histology-independent VE-Basket study
    Journal Article

    Subbiah, V.; Gervais, R.; Riely, G.; Hollebecque, A.; Blay, J. Y.; Felip, E.; Schuler, M.; Gonçalves, A.; Italiano, A.; Keedy, V.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
    Journal Article

    Razavi, P.; Li, B. T.; Brown, D. N.; Jung, B.; Hubbell, E.; Shen, R.; Abida, W.; Juluru, K.; De Bruijn, I.; Hou, C.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Molecular characteristics, immunophenotype, and immune checkpoint inhibitor response in BRAF non-V600 mutant lung cancers
    Meeting Abstract

    Offin, M.; Pak, T.; Mondaca, S.; Montecalvo, J.; Rekhtman, N.; Halpenny, D.; Wu, S.; Kris, M.; Paik, P.; Riely, G.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial
    Journal Article

    Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAF(V600) mutation
    Meeting Abstract

    Subbiah, V.; Gervais, R.; Riely, G. J.; Hollebecque, A.; Blay, J. Y.; Felip, E.; Schuler, M. H.; Goncalves, A.; Italiano, A.; Keedy, V. L.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save